Mechanism of Facilitating Cell-Mediated Tx Tolerance
Project Number5R01HL074150-04
Contact PI/Project LeaderCOLSON, YOLONDA L
Awardee OrganizationBRIGHAM AND WOMEN'S HOSPITAL
Description
Abstract Text
DESCRIPTION (provided by applicant):
The major goal in solid organ transplantation is to prevent rejection yet preserve recipient immunocompetence. Bone marrow (BM)-induced tolerance for solid organ and cellular grafts has been demonstrated in neonatal and adult models in several species, including humans, and may provide the means to overcome the current limitations hampering clinical organ transplantation. However, the morbidity and mortality associated with the infusion of unmodified BM into conditioned recipients has prevented clinical application to tolerance induction. The incidence and severity of graft vs. host disease (GVHD) is directly related to the degree of antigenic disparity between donor and recipient and is attributed to donor T cells in the BM inoculum. Clinical trials depleting these primary GVH effector cells, although successful in reducing GVHD, resulted in a concurrent rise in the incidence of engraftment failure. A rare donor BM-derived cell population called the facilitating cell (FC) is necessary and sufficient to permit engraftment of purified murine SC in completely MHC-disparate recipients, without GVHD. Although the FC does express CD8alphabeta and CD3epsilon and can be inadvertently removed as a T cell, the FC lacks the conventional T cell receptor (TCR) complex. Investigation into the dichotomy of CD3-TCR expression has revealed that TCRbeta gene rearrangement and expression does occur in the FC, but only in the context of a unique 33kD glycoprotein, named FCp33. Disulfide linked to the TCR beta chain as a heterodimer, FCp33 is distinct from any known TCR chain and is not present on mature T cells. The expression of the FCp33-TCR beta-CD3 complex is associated with allogeneic engraftment and the induction of donor-specific tolerance in the absence of clinical GVHD. Thus, the global aim of this proposal is to Determine the Mechanism of FC-Mediated Transplantation Tolerance. A number of developmentally-regulated markers have been identified on the cell surface of the FC, which suggest lymphoid ontogeny and recapitulation of lymphoid development. In AIM I, we will Identify the Ontogenic Pathway & Selection Events of FC Development. The co-expression of T cell-like markers and FCp33 on the FC, but absence on any known mature lymphoid lineages, suggests that FCp33 expression may play a transient role in the development of an unidentified progeny. AIM II will Characterize the Development of FC Progeny In Vivo. Whereas GVHD appears to be associated with the conventional T cell population, the responsibility for stem cell (SC) engraftment and the associated donor-specific tolerance rests with the FC, and FCp33 in particular, as donor-specific transplantation tolerance and FC facilitated SC engraftment fail to occur when FC without FCp33 expression are utilized. In AIM Ill, we will Determine the Mechanism of FC-Mediated Transplantation Tolerance.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
CD1 moleculeMHC class I antigenbone marrowbone marrow transplantationcell population studycell typegenetically modified animalsgraft versus host diseasehematopoietic stem cellshomologous transplantationlaboratory mousenatural killer cellstranscription factortransplantation immunology
No Sub Projects information available for 5R01HL074150-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL074150-04
Patents
No Patents information available for 5R01HL074150-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL074150-04
Clinical Studies
No Clinical Studies information available for 5R01HL074150-04
News and More
Related News Releases
No news release information available for 5R01HL074150-04
History
No Historical information available for 5R01HL074150-04
Similar Projects
No Similar Projects information available for 5R01HL074150-04